Mitigating the risk of Tofacitinib-induced adverse events in the elderly population with Ulcerative Colitis.

Modulation of induction dose and anti-thrombotic therapy may have contributed to prevent cardiologic events and thromboembolism. The introduction of zoster vaccine virtually eliminated zoster risk after the first cases. Potential malignancies deserve a careful work-up of older patients before treatment start.